196 related articles for article (PubMed ID: 33142025)
21. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
22. Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
Shaw J; Bulsara C; Cohen PA; Gryta M; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Hardcastle SJ
Patient Educ Couns; 2018 May; 101(5):938-944. PubMed ID: 29273311
[TBL] [Abstract][Full Text] [Related]
23. Family health beliefs and cascade genetic testing in Asian families with hereditary cancer risk: "Okay, now what?".
Tran L; Young JL; Barton CM; Hodan R; Hanson-Kahn A; Chun N
J Genet Couns; 2024 Mar; ():. PubMed ID: 38504135
[TBL] [Abstract][Full Text] [Related]
24. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors.
Berliner JL; Cummings SA; Boldt Burnett B; Ricker CN
J Genet Couns; 2021 Apr; 30(2):342-360. PubMed ID: 33410258
[TBL] [Abstract][Full Text] [Related]
25. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.
Bakos AD; Hutson SP; Loud JT; Peters JA; Giusti RM; Greene MH
Health Expect; 2008 Sep; 11(3):220-31. PubMed ID: 18816319
[TBL] [Abstract][Full Text] [Related]
26. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Arai M; Iwase T; Takazawa Y; Takeshima N
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
[TBL] [Abstract][Full Text] [Related]
27. Communicating genetic test results within the family: Is it lost in translation? A survey of relatives in the randomized six-step study.
Daly MB; Montgomery S; Bingler R; Ruth K
Fam Cancer; 2016 Oct; 15(4):697-706. PubMed ID: 26897130
[TBL] [Abstract][Full Text] [Related]
28. Testing for hereditary breast and ovarian cancer in the southeastern United States.
Miron A; Schildkraut JM; Rimer BK; Winer EP; Sugg Skinner C; Futreal PA; Culler D; Calingaert B; Clark S; Kelly Marcom P; Iglehart JD
Ann Surg; 2000 May; 231(5):624-34. PubMed ID: 10767783
[TBL] [Abstract][Full Text] [Related]
29. Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients.
Landsbergen K; Verhaak C; Kraaimaat F; Hoogerbrugge N
Fam Cancer; 2005; 4(2):115-9. PubMed ID: 15951961
[TBL] [Abstract][Full Text] [Related]
30. "Second-Class Status?" Insight into Communication Patterns and Common Concerns Among Men with Hereditary Breast and Ovarian Cancer Syndrome.
Suttman A; Pilarski R; Agnese DM; Senter L
J Genet Couns; 2018 Aug; 27(4):885-893. PubMed ID: 29404823
[TBL] [Abstract][Full Text] [Related]
31. Does a proactive procedure lead to a higher uptake of predictive testing in families with a pathogenic BRCA1/BRCA2 variant? A family cancer clinic evaluation.
Menko FH; van der Velden SL; Griffioen DN; Ait Moha D; Jeanson KN; Hogervorst FBL; Giesbertz NAA; Bleiker EMA; van der Kolk LE
J Genet Couns; 2023 Aug; ():. PubMed ID: 37605508
[TBL] [Abstract][Full Text] [Related]
32. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
[TBL] [Abstract][Full Text] [Related]
33. Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.
Flores KG; Steffen LE; McLouth CJ; Vicuña BE; Gammon A; Kohlmann W; Vigil L; Dayao ZR; Royce ME; Kinney AY
J Genet Couns; 2017 Jun; 26(3):480-490. PubMed ID: 27496122
[TBL] [Abstract][Full Text] [Related]
34. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
[TBL] [Abstract][Full Text] [Related]
36. Psychosocial barriers and facilitators for cascade genetic testing in hereditary breast and ovarian cancer: a scoping review.
Afaya A; Kim SW; Park HS; Lim MC; Jung MS; Nam EJ; Park JS; Jeong J; Ryu JM; Kim J; Kim J; Kim M; Jin J; Han J; Kim SY; Park SY; Katapodi MC; Kim S;
Fam Cancer; 2024 Apr; ():. PubMed ID: 38662264
[TBL] [Abstract][Full Text] [Related]
37. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
[TBL] [Abstract][Full Text] [Related]
38. Predictive testing for hereditary breast and ovarian cancer: a psychological framework for pre-test counselling.
Decruyenaere M; Evers-Kiebooms G; Denayer L; Welkenhuysen M; Claes E; Legius E; Demyttenaere K
Eur J Hum Genet; 2000 Feb; 8(2):130-6. PubMed ID: 10757645
[TBL] [Abstract][Full Text] [Related]
39. Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
Benusiglio PR; Korenbaum C; Vibert R; Ezenfis J; Geoffron S; Paul C; Richard S; Byrde V; Lejeune M; Guillerm E; Basset N; Lotz JP; Chabbert-Buffet N; Gligorov J; Coulet F
Eur J Med Genet; 2020 Dec; 63(12):104098. PubMed ID: 33186762
[TBL] [Abstract][Full Text] [Related]
40. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
Lerman C; Narod S; Schulman K; Hughes C; Gomez-Caminero A; Bonney G; Gold K; Trock B; Main D; Lynch J; Fulmore C; Snyder C; Lemon SJ; Conway T; Tonin P; Lenoir G; Lynch H
JAMA; 1996 Jun; 275(24):1885-92. PubMed ID: 8648868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]